NCT03114540View on ClinicalTrials.gov

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

March 22, 2018

Conditions
Hepatic Impairment
Interventions
DRUG

GBT440

Oral

Trial Locations (2)

32809

OCRC, Orlando

33136

University of Miami, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03114540 - Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment | Biotech Hunter | Biotech Hunter